Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 11, 1999, Pages 2635-2641

  Kuipers, M E ^a,c   De Vries, H G ^b   Eikelboom, M C ^a   Meijer, D K F ^a   Swart, P J ^a,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; IRON; LACTOFERRIN;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDIASIS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; HOST RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OROPHARYNX; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0032707616     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.11.2635     Document Type: Article

References (43)

1. Baily, G. G., F. M. Perry, D. W. Denning, and B. K. Mandal. 1994. Fluconazole-resistant candidosis in an HIV cohort. AIDS 8:787-792.
2. Barchiesi, F., L. F. DiFrancesco, P. Compagnucci, D. Arzeni, A. Giacometti, and G. Scalise. 1998. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J. Antimicrob. Chemother. 41:59-65.
3. Bellamy, W., H. Wakabayashi, M. Takase, K. Kawase, S. Shimamura, and M. Tomita. 1993. Killing of Candida albicans by lactoferrin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med. Microbiol. Immunol. 182:97-105.
4. Brock, J. H. 1980. Lactoferrin in human milk: its role in iron absorption and protection against enteric infection in the newborn infant. Arch. Dis. Child. 55:417-421.
5. Brummer, E., and D. A. Stevens. 1996. Synergy of human neutrophils with fluconazole in killing Candida species. Mycopathologia 134:115-120.
6. Bullen, J. J. 1981. The significance of iron in infection. Rev. Infect. Dis. 3:1127-1138.
7. Centers for Disease Control and Prevention. 1997. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists and AIDS Program, Center for Infectious Diseases. Morbid. Mortal. Weekly Rep. 36:1S-15S.
8. Cohen, M. S., J. Mao, G. T. Rasmussen, J. S. Serody, and B. E. Britigan. 1992. Interaction of lactoferrin and lipopolysaccharide (LPS): effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation. J. Infect. Dis. 166:1375-1378.
9. Force, R. W., and M. C. Nahata. 1995. Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. Ann. Pharmacother. 29:10-15.
10. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329.
11. Garcia Hermoso, D., F. Dromer, L. Improvisi, F. Provost, and B. Dupont. 1995. Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole. Antimicrob. Agents Chemother. 39:656-660.
12. Harmsen, M. C., P. J. Swart, M.-P. de Bétbune, R. Pauwels, E. De Clercq, T. H. The, and D. K. F. Meijer. 1995. Antiviral effects of plasma and milk proteins: lactoferrin shows potent antiviral activity on both human immunodeficiency virus and human cytomegalovirus. J. Infect. Dis. 172:380-388.
13. Hood, S., and D. W. Denning. 1996. Treatment of fungal infection in AIDS. J. Antimicrob. Chemother. 37(Suppl. B):71-85.
14. Kerridge, D., and R. O. Nicholas. 1986. Drug resistance in the opportunistic pathogens Candida albicans and Candida glabrata. J. Antimicrob. Chemother. 18:39-49.
15. Kirkpatrick, C. H., I. Green, R. R. Rich, and A. L. Schade. 1971. Inhibition of growth of Candida albicans by iron-unsaturated lactoferrin: relation to host-defense mechanisms in chronic mucocutaneous candidiasis. J. Infect. Dis. 124:539-544.
16. Kuipers, M. E., H. G. de Vries, J. H. Heegsma, J. J. M. van den Berg, D. K. F. Meyer, and P. J. Swart. Conditions influencing the antifungal activity of lactoferrin and antifungal drugs against clinical isolates of Candida. Submitted for publication.
17. Langenbeck, B. 1839. Auffingung von Pilzen aus der Schleimhaut der Speiseröhre einer Typhus-Leiche. Neue Not. Geb. Natur-u-Heilk (Froriep) 12: 145-147.
18. Lyman, C. A., and T. J. Walsh. 1992. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44:9-35.
19. Marchetti, M., C. Longhi, M. P. Conte, S. Pisani, P. Valenti, and L. Seganti. 1996. Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells. Antiviral Res. 29:221-231.
20. Masson, P. L., and J. F. Heremans. 1968. Metal-combining properties of human lactoferrin (red milk protein): the involvement of bicarbonate in the reaction. Eur. J. Biochem. 6:579-584.
21. Nassar, F., E. Brummer, and D. A. Stevens. 1995. Different components in human serum inhibit multiplication of Cryptococcus neofarmans and enhance fluconazole activity. Antimicrob. Agents Chemother. 39:2490-2493.
22. Natarajan, U., N. Randhawa, E. Brummer, and D. A. Stevens. 1998. Effect of granulocyte-macrophage colony-stimulating factor on candidacidal activity of neutrophil, monocytes or monocyte-derived macrophages and synergy with fluconazole. J. Med. Microbiol. 47:359-363.
23. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeast. Tentative standard M27-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
24. Nikawa, H., L. P. Samaranayake, J. Tenovuo, and T. Hamada. 1994. The effect of antifungal agents on the in vitro susceptibility of Candida albicans to apo-lactoferrin. Arch. Oral Biol. 39:921-923.
25. Nikawa, H., L. P. Samaranayake, J. Tenovuo, K. M. Pang, and T. Hamada. 1993. The fungicidal effect of human lactoferrin on Candida albicans and Candida krusei. Arch. Oral Biol. 38:1057-1063.
26. Odds, F. C. 1988. Candida and candidosis. A review and bibliography, p. 93-114. Baillière Tindall, London, United Kingdom.
27. Okutomi, T., S. Abe, S. Tansho, H. Wakabayashi, K. Kawase, and H. Yamaguchi. 1997. Augmented inhibition of growth of Candida albicans by neutrophils in the presence of lactoferrin. FEMS Immunol. Med. Microbiol. 18:105-112.
28. Oppenheim, F. G., T. Xu, F. M. McMillian, S. M. Levitz, R. D. Diamond, G. D. Offner, and R. F. Troxler. 1988. Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J. Biol. Chem. 263: 7472-7477.
29. Osaka, K., V. B. Ritov, J. F. Bernardo, R. A. Branch, and V. E. Kagan. 1997. Amphothericin B protects cis-parinaric acid against peroxyl radical-induced oxidation: amphotericin B as an antioxidant. Antimicrob. Agents Chemother. 41:743-747.
30. Pfaller, M. A., L. Burmeister, M. S. Bartlett, and M. G. Rinaldi. 1988. Multicenter evaluation of four methods of yeast inoculum preparation. J. Clin. Microbiol. 26:1437-1441.
31. Plettenberg, A., A. Stoehr, G. Hoffken, C. Bergs, B. Tschechne, M. Ruhnke, W. Heise, S. Dieckmann, and W. Meigel. 1994. Fluconazole therapy of oral candidiasis in HIV-infected patients: results of a multicentre study. Infection 22:118-123.
32. Pollock, J. J., L. Denepitiya, B. J. Mackay, and V. J. Iacona. 1984. Fungistatic and fungicidal activity of human parotid salivary histidine-rich polypeptides on Candida albicans. Infect. Immun. 44:702-707.
33. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-206.
34. Reiter, B. 1983. The biological significance of lactoferrin. Int. J. Tissue React. 5:87-96.
35. Samaranayake, L. P. 1990. Host factors and oral candidosis, p. 66-103. In L. P. Samaranayake and T. W. MacFarlane. (ed.), Oral candidosis. Wright, London, United Kingdom.
36. Scott, E. M., V. N. Tariq, and R. M. McCrory. 1995. Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. Antimicrob. Agents Chemother. 39:2610-2614.
37. Sokol-Anderson, M. L., J. Brajtburg, and G. Medof. 1986. Amphotericin B-induced oxidative damage and killing of Candida albicans. J. Infect. Dis. 154:75-83.
38. Soukka, T., J. Tenovuo, and M. Lenander Lumikari. 1992. Fungicidal effect of human lactoferrin against Candida albicans. FEMS Microbiol. Lett. 69: 223-228.
39. Swart, P. J., M. E. Kuipers, C. Smit, B. W. A. van der Strate, M. C. Harmsen, and D. K. F. Meijer. 1998. Lactoferrin: antiviral activity of lactoferrin, p. 205-213. In G. Spik, D. Legrand, J. Mazurier, A. Pierce, and J. Perraudin. (ed.), Advances in lactoferrin research. Plenum Press, New York, N.Y.
40. Tumbarello, M., G. Caldarola, E. Tacconelli, G. Morace, B. Posteraro, R. Cauda, and L. Ortona. 1996. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. J. Antimicrob. Chemother. 38:691-699.
41. van der Strate, B. W. A., M. C. Harmsen, T. H. The, H. Sprenger, M. C. Eikelboom, M. E. Kuipers, D. K. F. Meijer, and P. J. Swart. Plasma lactoferrin levels are decreased in end-stage AIDS patients. Viral Immunol., in press.
42. Wakabayashi, H., S. Abe, T. Okutomi, S. Tansho, K. Kawase, and H. Yamaguchi. 1996. Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol. Immunol. 40: 821-825.
43. Wakabayashi, H., S. Abe, S. Teraguchi, H. Hayasawa, and H. Yamaguchi. 1998. Inhibition of hyphal growth of azole-resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compounds. Antimicrob. Agents Chemother. 42:1587-1591.